- Účinnost natalizumabu u pacientů s relabující roztroušenou sklerózou : analýzy podskupin AFFIRM a SENTINEL2009 | 1. lékařská fakulta
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis : CLARIFY-MS study 6-month interim analysis2022 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting2006 | 1. lékařská fakulta
- A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting2006 | Fakulta tělesné výchovy a sportu
- A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis2006 | 1. lékařská fakulta
- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program2021 | 1. lékařská fakulta
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosis2007 | 1. lékařská fakulta
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosis2007 | Fakulta tělesné výchovy a sportu
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis2010 | 2. lékařská fakulta
- Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis2015 | 1. lékařská fakulta
- The effects of natalizumab on a test of cognitive function in patients with relapsing multiple sclerosis (MS)Publikace bez příslušnosti k fakultě
- Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis2012 | 2. lékařská fakulta
- Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study2022 | Lékařská fakulta v Hradci Králové
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE) : a multicentre, randomised, 24-month, phase 3 trial2019 | 1. lékařská fakulta
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial2019 | 1. lékařská fakulta
- Přechod na léčbu fingolimodem oproti setrvání v léčbě glatiramer acetátem nebo interferonem Beta u pacientů s relabující roztroušenou sklerózou: Následná analýza klinické studie EPOC2015 | Publikace bez příslušnosti k fakultě
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study A Randomized Clinical Trial2021 | 1. lékařská fakulta
- Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial2012 | 1. lékařská fakulta
- Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study2023 | 1. lékařská fakulta
- Understanding the positive benefit: risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program2017 | 1. lékařská fakulta, 2. lékařská fakulta
- No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a2018 | 1. lékařská fakulta
- Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis2022 | 1. lékařská fakulta, Lékařská fakulta v Hradci Králové
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | 1. lékařská fakulta
- Clinical results from AFFIRM: a randomized, double-blind, placebo-controlled, multicenter trial to determine the efficacy and safety of Natalizumab in patients with relapsing multiple sclerosisPublikace bez příslušnosti k fakultě
- The incidence and significance of anti-natalizumab antibodies - Results from AFFIRM and SENTINEL2007 | 2. lékařská fakulta
- Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence2023 | 1. lékařská fakulta
- Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS2016 | 1. lékařská fakulta
- Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studies2023 | 1. lékařská fakulta
- Léčba roztroušené sklerózy perorálním kladribinem - výsledky klinických hodnocení2017 | 1. lékařská fakulta
- Zpráva FNHK ke klinickému hondocení č. protokolu WA21092Publikace bez příslušnosti k fakultě